Mathematical characterization of population dynamics in breast cancer cells treated with doxorubicin

被引:9
|
作者
Yang, Emily Y. [1 ]
Howard, Grant R. [2 ]
Brock, Amy [2 ,3 ,4 ]
Yankeelov, Thomas E. [1 ,2 ,3 ,5 ,6 ,7 ]
Lorenzo, Guillermo [1 ,8 ]
机构
[1] Univ Texas Austin, Oden Inst Computat Engn & Sci, Austin, TX 78712 USA
[2] Univ Texas Austin, Dept Biomed Engn, Austin, TX 78712 USA
[3] Univ Texas Austin, Dell Med Sch, Livestrong Canc Inst, Austin, TX 78712 USA
[4] Univ Texas Austin, Interdisciplinary Life Sci Program, Austin, TX 78712 USA
[5] Univ Texas Austin, Dept Diagnost Med, Austin, TX 78712 USA
[6] Univ Texas Austin, Dept Oncol, Austin, TX 78712 USA
[7] Univ Texas MD Anderson Canc Ctr, Dept Imaging Phys, Houston, TX 77030 USA
[8] Univ Pavia, Dept Civil Engn & Architecture, Pavia, Italy
基金
美国国家卫生研究院;
关键词
mathematical oncology; mathematical modeling; population dynamics; chemotherapy; drug resistance; breast cancer; time-resolved microscopy; DRUG-RESISTANCE; TUMOR HETEROGENEITY; DOSE-DENSE; NEOADJUVANT THERAPY; RANDOMIZED-TRIAL; LOGISTIC MODEL; CHEMOTHERAPY; MECHANISMS; SCHEDULE; SURVIVAL;
D O I
10.3389/fmolb.2022.972146
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The development of chemoresistance remains a significant cause of treatment failure in breast cancer. We posit that a mathematical understanding of chemoresistance could assist in developing successful treatment strategies. Towards that end, we have developed a model that describes the cytotoxic effects of the standard chemotherapeutic drug doxorubicin on the MCF-7 breast cancer cell line. We assume that treatment with doxorubicin induces a compartmentalization of the breast cancer cell population into surviving cells, which continue proliferating after treatment, and irreversibly damaged cells, which gradually transition from proliferating to treatment-induced death. The model is fit to experimental data including variations in drug concentration, inter-treatment interval, and number of doses. Our model recapitulates tumor cell dynamics in all these scenarios (as quantified by the concordance correlation coefficient, CCC > 0.95). In particular, superior tumor control is observed with higher doxorubicin concentrations, shorter inter-treatment intervals, and a higher number of doses (p < 0.05). Longer inter-treatment intervals require adapting the model parameterization after each doxorubicin dose, suggesting the promotion of chemoresistance. Additionally, we propose promising empirical formulas to describe the variation of model parameters as functions of doxorubicin concentration (CCC > 0.78). Thus, we conclude that our mathematical model could deepen our understanding of the cytotoxic effects of doxorubicin and could be used to explore practical drug regimens achieving optimal tumor control.
引用
收藏
页数:21
相关论文
共 50 条
  • [21] Allicin Overcomes Doxorubicin Resistance of Breast Cancer Cells by Targeting the Nrf2 Pathway
    Shi, Guojian
    Li, Xiaohua
    Wang, Weiping
    Hou, Lili
    Yin, Lei
    Wang, Li
    CELL BIOCHEMISTRY AND BIOPHYSICS, 2024, 82 (02) : 659 - 667
  • [22] Lysyl Oxidase Propeptide Sensitizes Pancreatic and Breast Cancer Cells to Doxorubicin-Induced Apoptosis
    Min, Chengyin
    Zhao, Yingshe
    Romagnoli, Mathilde
    Trackman, Philip C.
    Sonenshein, Gail E.
    Kirsch, Kathrin H.
    JOURNAL OF CELLULAR BIOCHEMISTRY, 2010, 111 (05) : 1160 - 1168
  • [23] Effective response of doxorubicin-sensitive and -resistant breast cancer cells to combinational siRNA therapy
    Aliabadi, Hamidreza Montazeri
    Maranchuk, Robert
    Kucharski, Cezary
    Mahdipoor, Parvin
    Hugh, Judith
    Uludag, Hasan
    JOURNAL OF CONTROLLED RELEASE, 2013, 172 (01) : 219 - 228
  • [24] Expression of the hemochromatosis gene modulates the cytotoxicity of doxorubicin in breast cancer cells
    Chitambar, Christopher R.
    Kotamraju, Srigiridhar
    Wereley, Janine P.
    INTERNATIONAL JOURNAL OF CANCER, 2006, 119 (09) : 2200 - 2204
  • [25] Does insulin make breast cancer cells resistant to doxorubicin toxicity?
    Oleksandra Lykhova
    Michael Zavelevich
    Alex Philchenkov
    Nazar Vidasov
    Tamara Kozak
    Yulia Lozovska
    Iryna Andrusyshyna
    Anupam Bishayee
    Tetiana Borikun
    Natalia Lukianova
    Vasyl Chekhun
    Naunyn-Schmiedeberg's Archives of Pharmacology, 2023, 396 : 3111 - 3122
  • [26] Epirubicin: Is it like doxorubicin in breast cancer? A clinical review
    Khasraw, Mustafa
    Bell, Richard
    Dang, Chau
    BREAST, 2012, 21 (02) : 142 - 149
  • [27] The opposite effects of doxorubicin on bone marrow stem cells versus breast cancer stem cells depend on glucosylceramide synthase
    Bhinge, Kaustubh N.
    Gupta, Vineet
    Hosain, Salman B.
    Satyanarayanajois, Seetharama D.
    Meyer, Sharon A.
    Blaylock, Benny
    Zhang, Qian-Jin
    Liu, Yong-Yu
    INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2012, 44 (11) : 1770 - 1778
  • [28] Synergistic treatment of doxorubicin-resistant breast cancer by the combination of chemotherapy and photodynamic therapy
    Yang, Yuguang
    Cui, Wei
    Zhao, Jie
    COLLOIDS AND SURFACES A-PHYSICOCHEMICAL AND ENGINEERING ASPECTS, 2022, 648
  • [29] Analysis of miRNA expression profile induced by short term starvation in breast cancer cells treated with doxorubicin
    Rizzo, Sergio
    Cangemi, Antonina
    Galvano, Antonio
    Fanale, Daniele
    Buscemi, Silvio
    Ciaccio, Marcello
    Russo, Antonio
    Castorina, Sergio
    Bazan, Viviana
    ONCOTARGET, 2017, 8 (42): : 71924 - 71932
  • [30] Characterization of metastatic breast cancer patients with nondetectable circulating tumor cells
    Mego, Michal
    De Giorgi, Ugo
    Dawood, Shahenaah
    Wang, Xuemei
    Valero, Vicente
    Andreopoulou, Eleni
    Handy, Beverly
    Ueno, Naoto T.
    Reuben, James M.
    Cristofanilli, Massimo
    INTERNATIONAL JOURNAL OF CANCER, 2011, 129 (02) : 417 - 423